Astra and Daiichi beat Gilead to the punch, at least in one setting.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
After trimming its cell therapy pipeline last year, the group is now out entirely.
A Chinese phase 3 of the biparatopic DLL3 T-cell engager alveltamig will start soon.
The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.
A single-arm trial was enough for J&J’s Inlexzo nod.
The Kandlelit-007 trial will assess MK-1084 plus SC Keytruda across PD-L1 expression levels.
ESMO and the Triple Meeting approach.